Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2023-03-28 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于召开2022年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2022 Annual General Meeting (AGM) of Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes information about the meeting date, voting procedures, agenda items including the 2022 annual report and other proposals, shareholder registration, and proxy voting instructions. The document does not contain the actual annual report or financial statements but rather the notification and procedural details for the AGM. This matches the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or notices about the AGM itself. The document length is over 6,000 characters and contains detailed meeting information, not just a brief announcement, so it is not a Report Publication Announcement (RPA). Therefore, the correct classification is AGM Information (AGM-R).
2023-03-28 Chinese
关于使用自有闲置资金投资理财产品的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the use of its own idle funds to invest in low-risk, short-term financial products. It details the investment purpose, amount, method, duration, risk analysis, and approvals by the board, independent directors, and supervisory board. The document is a formal disclosure of a financing-related decision by the company, specifically about investing idle funds in financial products, which is a capital management activity. It is not a full financial report, audit, or earnings release, nor is it a regulatory certification or voting result. The document length is 3583 characters, which is relatively short but contains substantive information about the financing decision. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2023-03-28 Chinese
年度募集资金使用情况专项说明
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the use and management of funds raised by Shenzhen Salubris Pharmaceuticals Co., Ltd. in 2022. It includes specifics on the amount raised, usage of funds, storage, investment projects, and compliance with regulatory requirements. The document references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and it is titled as a "special report on the storage and actual use of raised funds for the year 2022." The content focuses on the management and deployment of capital raised through a non-public stock issuance, including detailed financial figures and project progress. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is substantive and not merely an announcement or certification, and it is not a full annual or interim report. Therefore, the appropriate classification is CAP with high confidence.
2023-03-28 Chinese
华英证券有限责任公司关于深圳信立泰药业股份有限公司非公开发行A股股票之保荐工作总结报告书
Capital/Financing Update Classification · 95% confidence The document is titled as a "保荐工作总结报告书" which translates to "Sponsorship Work Summary Report" by 华英证券 for 深圳信立泰药业股份有限公司 regarding a non-public issuance of A shares. It details the sponsorship institution's responsibilities, due diligence, continuous supervision, and compliance with regulatory requirements related to the non-public share issuance completed in 2021. The document includes summaries of the sponsorship work, legal compliance, and fund usage but does not contain financial statements or detailed financial performance data. It is a summary report of the sponsorship work related to a capital raising event rather than a direct financial report or earnings release. Given the content and nature, this fits best under Capital/Financing Update (CAP) as it relates to the non-public issuance of shares and the sponsorship work summary for that financing event. The document length is 3339 characters, which is substantive and not a mere announcement or certification, supporting classification as CAP rather than RPA or RNS.
2023-03-28 Chinese
关于分拆所属子公司深圳信立泰医疗器械股份有限公司至科创板上市的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed special verification opinion and explanatory statement regarding the spin-off and listing of a subsidiary (Shenzhen Xinlitai Medical Device Co., Ltd.) on the STAR Market (科创板) in China. It references compliance with the China Securities Regulatory Commission's (CSRC) Listing Company Spin-off Rules (Trial) and includes financial data, management resolutions, and compliance confirmations. The document is issued by a certified public accounting firm and includes audit opinions related to the spin-off. It is not a full annual or interim financial report, nor is it a simple announcement or certification. Instead, it is a specialized audit and verification report focused on the spin-off transaction and its regulatory compliance. This fits the definition of an Audit Report / Information (AR) filing, which includes standalone audit reports and applied accounting principles related to specific regulatory matters, excluding full annual reports. FY 2022
2023-03-28 Chinese
深圳信立泰药业股份有限公司关于分拆所属子公司深圳信立泰医疗器械股份有限公司至科创板上市的预案
Capital/Financing Update Classification · 95% confidence The document is a detailed plan and proposal regarding the spin-off and listing of a subsidiary company (Shenzhen Xinlitai Medical Device Co., Ltd.) on the Shanghai Stock Exchange's Science and Technology Innovation Board (科创板). It includes extensive information about the background, purpose, business rationale, regulatory compliance, risk factors, and the decision-making and approval process related to the spin-off and IPO. The document is titled as a "预案" (proposal or plan) and contains no actual financial statements or audited financial results but rather outlines the intended transaction and regulatory steps. This type of document is characteristic of a Capital/Financing Update (CAP), as it provides updates on a significant capital restructuring and financing event (spin-off and IPO). It is not an Annual Report, Interim Report, or Earnings Release, nor is it a regulatory filing or announcement of voting results. The length and detail confirm it is not a mere announcement but a substantive proposal document. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-03-28 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.